id,group_id,source,exact,prefix,suffix,anno_type,position_type,start,end,tags,all,origin_tags,comment,user,title,created
zkFFIuwfEem6iaNLql-K2g,b53nbDmi,https://europepmc.org/articles/PMC5999171/,EPCAM,"r PMS2, or in the 3′ end of the ", gene and consequent hypermethyl,TextQuoteSelector,TextPositionSelector,12120,12125,CRT_GP,no,CRT_GP,,acct:vanitha_hg@hypothes.is,Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers.,2019-10-11T12:08:15.635539+00:00
xtvJJOwfEemNrF9lKGGgNA,b53nbDmi,https://europepmc.org/articles/PMC5999171/,MMR, in one of the mismatch repair (,") genes MLH1, MSH2, MSH6 or PMS2",TextQuoteSelector,TextPositionSelector,12059,12062,WT_GP,yes,[WT_GP][ALL],,acct:vanitha_hg@hypothes.is,Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers.,2019-10-11T12:08:03.114383+00:00
vuXHQuwfEemXNntZK0ZjFA,b53nbDmi,https://europepmc.org/articles/PMC5999171/,colonic cancers,ometrial cancer and other extra-," at a young age [1, 2]. Morbidit",TextQuoteSelector,TextPositionSelector,11796,11811,CRT_DS,no,CRT_DS,,acct:vanitha_hg@hypothes.is,Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers.,2019-10-11T12:07:50.021652+00:00
v_8IIuwgEemIB_dJBf5O8Q,b53nbDmi,https://europepmc.org/articles/PMC5999171/,cancers,4 years [49–57]0.18 Multiple LS ,4% (27)13% (11)0.002First degree,TextQuoteSelector,TextPositionSelector,21855,21862,MIS_DS,yes,[MIS_DS][ALL],,acct:vanitha_hg@hypothes.is,Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers.,2019-10-11T12:15:01.355516+00:00
ukwl4OwgEem2fWOtg9ZaOA,b53nbDmi,https://europepmc.org/articles/PMC5999171/, Endometrial cancer,  ≥ 2 CRCs10% (66)21% (17)0.005 ,3% (11)41% (17)<0.001   Age EC (,TextQuoteSelector,TextPositionSelector,21743,21762,MIS_DS,yes,[MIS_DS][ALL],,acct:vanitha_hg@hypothes.is,Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers.,2019-10-11T12:14:51.682754+00:00
uW8_-uwfEemXNad_z1WJjQ,b53nbDmi,https://europepmc.org/articles/PMC5999171/,endometrial cancer,"sposition to colorectal cancer, ", and other extra-colonic cancers,TextQuoteSelector,TextPositionSelector,11761,11779,CRT_DS,no,CRT_DS,,acct:vanitha_hg@hypothes.is,Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers.,2019-10-11T12:07:40.836681+00:00
stp7UOwfEem0QIuh7Y871Q,b53nbDmi,https://europepmc.org/articles/PMC5999171/,Lynch syndrome,editary cancerGo to:Introduction, (LS) is a hereditary predisposi,TextQuoteSelector,TextPositionSelector,11688,11702,MIS_DS,yes,[MIS_DS][ALL],,acct:vanitha_hg@hypothes.is,Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers.,2019-10-11T12:07:29.469934+00:00
raBC-uwfEemrAGeNNFuG_w,b53nbDmi,https://europepmc.org/articles/PMC5999171/,Hereditary cancer,"tion models, Colorectal cancer, ",Go to:IntroductionLynch syndrome,TextQuoteSelector,TextPositionSelector,11653,11670,MIS_DS,no,MIS_DS,,acct:vanitha_hg@hypothes.is,Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers.,2019-10-11T12:07:20.998879+00:00
oWuXbuwfEemDpa9v5fKS_Q,b53nbDmi,https://europepmc.org/articles/PMC5999171/,Colorectal cancer,"ch syndrome, Prediction models, ",", Hereditary cancerGo to:Introdu",TextQuoteSelector,TextPositionSelector,11634,11651,MIS_DS,no,MIS_DS,,acct:vanitha_hg@hypothes.is,Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers.,2019-10-11T12:07:00.478081+00:00
mXBRXOwgEem8qMc_EWqJIA,b53nbDmi,https://europepmc.org/articles/PMC5999171/,CRC,9 years [39–59]0.002   Proximal ,28% (185)64% (53)<0.001   ≥ 2 CR,TextQuoteSelector,TextPositionSelector,21684,21687,MIS_DS,yes,[MIS_DS][ALL],,acct:vanitha_hg@hypothes.is,Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers.,2019-10-11T12:13:56.665671+00:00
l0IHAOwfEemIZ0fbjlVzvA,b53nbDmi,https://europepmc.org/articles/PMC5999171/,colorectal cancer,ts in an external cohort of 376 ," patients, including 158 LS pati",TextQuoteSelector,TextPositionSelector,11155,11172,WS_DS,no,WS_DS,,acct:vanitha_hg@hypothes.is,Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers.,2019-10-11T12:06:43.356569+00:00
iEMM0OwgEem9VefEBmvJCA,b53nbDmi,https://europepmc.org/articles/PMC5999171/,women,an non-mutation carriers. Among ,", the frequency of EC was higher",TextQuoteSelector,TextPositionSelector,20937,20942,MIS_OG,no,MIS_OG,,acct:vanitha_hg@hypothes.is,Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers.,2019-10-11T12:13:27.699113+00:00
hfUJrOwfEemucjOlSWJ-iw,b53nbDmi,https://europepmc.org/articles/PMC5999171/,colorectal cancer,rriers was proximal location of ," (77 vs. 28%, p<0.001). Adding l",TextQuoteSelector,TextPositionSelector,10895,10912,CRT_DS,yes,[CRT_DS][ALL],,acct:vanitha_hg@hypothes.is,Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers.,2019-10-11T12:06:14.318426+00:00
eZYoFuwgEemW_IcLVo5F8A,b53nbDmi,https://europepmc.org/articles/PMC5999171/,cancers,005) and multiple LS-associated ," in general (13 vs. 4%, p=0.002)",TextQuoteSelector,TextPositionSelector,20688,20695,CRT_DS,no,CRT_DS,,acct:vanitha_hg@hypothes.is,Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers.,2019-10-11T12:13:03.244925+00:00
e8nfZuwfEemgzm8VeLHolg,b53nbDmi,https://europepmc.org/articles/PMC5999171/,MSH6,79 for MMRpredict) and fair for , mutation carriers (0.69 for PRE,TextQuoteSelector,TextPositionSelector,10538,10542,CRT_GP,yes,[CRT_GP][ALL],,acct:vanitha_hg@hypothes.is,Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers.,2019-10-11T12:05:57.210894+00:00
deIDEuwfEemt-0M_meSqMw,b53nbDmi,https://europepmc.org/articles/PMC5999171/,MSH2,els performed well for MLH1 and , (AUC 0.80 and 0.83 for PREMM5 a,TextQuoteSelector,TextPositionSelector,10465,10469,CRT_GP,yes,[CRT_GP][ALL],,acct:vanitha_hg@hypothes.is,Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers.,2019-10-11T12:05:47.401040+00:00
cGDsquwfEemzbUM04qRcSA,b53nbDmi,https://europepmc.org/articles/PMC5999171/,MLH1,ction models performed well for , and MSH2 (AUC 0.80 and 0.83 for,TextQuoteSelector,TextPositionSelector,10456,10460,CRT_GP,yes,[CRT_GP][ALL],,acct:vanitha_hg@hypothes.is,Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers.,2019-10-11T12:05:38.276748+00:00
bUpkyO8xEemhGWP6XDPFOw,b53nbDmi,https://europepmc.org/articles/PMC5999171/,Lynch syndrome patients were PMS2 ," our cohort, 14% (12/83) of the ",mutation carriers. To our knowle,TextQuoteSelector,TextPositionSelector,34059,34093,YGD,no,YGD,,acct:vanitha_hg@hypothes.is,Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers.,2019-10-15T09:51:57.575582+00:00
awhDKuwfEemt-k9nVZaRAQ,b53nbDmi,https://europepmc.org/articles/PMC5999171/,PMS2 ,"3 MLH1, 17 MSH2, 31 MSH6 and 12 ",mutation carriers. Both predicti,TextQuoteSelector,TextPositionSelector,10390,10395,MIS_GP,yes,[MIS_GP][ALL],,acct:vanitha_hg@hypothes.is,Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers.,2019-10-11T12:05:29.088579+00:00
agD3Hu8xEemRdDfb65RxSw,b53nbDmi,https://europepmc.org/articles/PMC5999171/, Lynch syndrome cases are estimated to be caused by PMS2,ted penetrance.Around 15% of all," mutations [38]. In our cohort, ",TextQuoteSelector,TextPositionSelector,33952,34008,YGD,no,YGD,,acct:vanitha_hg@hypothes.is,Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers.,2019-10-15T09:51:51.964388+00:00
Zj9BVOwfEemiVDdHNOCzyg,b53nbDmi,https://europepmc.org/articles/PMC5999171/,MSH6 ,"d with LS; 23 MLH1, 17 MSH2, 31 ",and 12 PMS2 mutation carriers. B,TextQuoteSelector,TextPositionSelector,10378,10383,MIS_GP,yes,[MIS_GP][ALL],,acct:vanitha_hg@hypothes.is,Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers.,2019-10-11T12:05:21.150779+00:00
ZSF91u8xEemqznch_kqjRg,b53nbDmi,https://europepmc.org/articles/PMC5999171/,Lynch syndrome and in our cohort was the only significant difference between PMS2,of CRC is a known predictor for , mutation carriers and non-mutat,TextQuoteSelector,TextPositionSelector,30415,30496,YGD,no,YGD,,acct:vanitha_hg@hypothes.is,Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers.,2019-10-15T09:51:43.873335+00:00
ZCNcGuwgEemudfMohrHDLg,b53nbDmi,https://europepmc.org/articles/PMC5999171/,CRCs,t of the predictor ‘Two or more ,’ in the linear predictor for MS,TextQuoteSelector,TextPositionSelector,19045,19049,MIS_DS,yes,[MIS_DS][ALL],,acct:vanitha_hg@hypothes.is,Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers.,2019-10-11T12:12:27.239571+00:00
YPWEMu8xEemJ03_Qx2jrCw,b53nbDmi,https://europepmc.org/articles/PMC5999171/,tumour location also improved the performance of PREMM5 for identifying MLH1,"ndividual MMR mutations

Adding ", (AUC 0.92 [95% CI 0.88–0.97] vs,TextQuoteSelector,TextPositionSelector,27221,27297,YGD,no,YGD,,acct:vanitha_hg@hypothes.is,Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers.,2019-10-15T09:51:36.803095+00:00
XC4A4uwfEemiUytcV8QHag,b53nbDmi,https://europepmc.org/articles/PMC5999171/,MSH2," diagnosed with LS; 23 MLH1, 17 ",", 31 MSH6 and 12 PMS2 mutation c",TextQuoteSelector,TextPositionSelector,10369,10373,MIS_GP,yes,[MIS_GP][ALL],,acct:vanitha_hg@hypothes.is,Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers.,2019-10-11T12:05:04.295205+00:00
WrUSUOwfEemMYg9sjJskHQ,b53nbDmi,https://europepmc.org/articles/PMC5999171/,MLH1,11%) were diagnosed with LS; 23 ,", 17 MSH2, 31 MSH6 and 12 PMS2 m",TextQuoteSelector,TextPositionSelector,10360,10364,MIS_GP,yes,[MIS_GP][ALL],,acct:vanitha_hg@hypothes.is,Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers.,2019-10-11T12:05:01.584868+00:00
WV686OwgEemNqK9sTLGfwQ,b53nbDmi,https://europepmc.org/articles/PMC5999171/,TACSTD1,"ng a mutation in MLH1, MSH2 (or ","), MSH6 and PMS2. The coefficien",TextQuoteSelector,TextPositionSelector,18595,18602,CRT_GP,no,CRT_GP,,acct:vanitha_hg@hypothes.is,Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers.,2019-10-11T12:12:09.177639+00:00
WRkm2O8xEem9puuxOlS3WQ,b53nbDmi,https://europepmc.org/articles/PMC5999171/,MLH1 promoter methylation analysis to exclude sporadic MMR deficient tumours,"s of MSI and IHC, combined with ",", are used to identify patients ",TextQuoteSelector,TextPositionSelector,12364,12440,YGD,no,YGD,,acct:vanitha_hg@hypothes.is,Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers.,2019-10-15T09:51:23.579623+00:00
VSqd4O8xEemmfmfppcEj1A,b53nbDmi,https://europepmc.org/articles/PMC5999171/, colorectal cancer to PREMM5 considerably improved the models performance for PMS2 ,"8%, p<0.001). Adding location of",mutation carriers (AUC 0.77) and,TextQuoteSelector,TextPositionSelector,10913,10996,YGD,no,YGD,,acct:vanitha_hg@hypothes.is,Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers.,2019-10-15T09:51:16.952907+00:00
UUoYIu8xEemdBqOtrl7uXA,b53nbDmi,https://europepmc.org/articles/PMC5999171/, PMS2 mutation carriers and non-mutation carriers was proximal location of colorectal cancer,y significant difference between," (77 vs. 28%, p<0.001). Adding l",TextQuoteSelector,TextPositionSelector,10779,10871,YGD,no,YGD,,acct:vanitha_hg@hypothes.is,Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers.,2019-10-15T09:51:10.502518+00:00
Tad44O8xEemEBz-gSqI5LA,b53nbDmi,https://europepmc.org/articles/PMC5999171/,Lynch syndrome: updating the PREMM5 model to identify PMS2,f current prediction models for ," mutation carriersA. Goverde,1,2",TextQuoteSelector,TextPositionSelector,6130,6188,YGD,no,YGD,,acct:vanitha_hg@hypothes.is,Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers.,2019-10-15T09:51:04.306061+00:00
TFs1_uwfEem8HnOeuC8b3g,b53nbDmi,https://europepmc.org/articles/PMC5999171/,LS,tion models for Lynch syndrome (,) had been validated for PMS2 mu,TextQuoteSelector,TextPositionSelector,9856,9858,MIS_DS,yes,[MIS_DS][ALL],,acct:vanitha_hg@hypothes.is,Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers.,2019-10-11T12:04:37.721569+00:00
RYHhOOwfEemznAtp2vvI4g,b53nbDmi,https://europepmc.org/articles/PMC5999171/,PMS2,ng the PREMM5 model to identify ," mutation carriersA. Goverde,1,2",TextQuoteSelector,TextPositionSelector,6225,6229,CRT_GP,yes,[CRT_GP][ALL],,acct:vanitha_hg@hypothes.is,Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers.,2019-10-11T12:04:26.374242+00:00
RP4tau8xEemmfXMNatWVGA,b53nbDmi,https://europepmc.org/articles/PMC5999171/,Lynch syndrome (LS) had been validated for PMS2,"ently, no prediction models for ", mutation carriers. We aimed to ,TextQuoteSelector,TextPositionSelector,9799,9846,NGD,no,NGD,,acct:vanitha_hg@hypothes.is,Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers.,2019-10-15T09:50:49.858236+00:00
QTLOvOwfEemiJhvTOcZXCg,b53nbDmi,https://europepmc.org/articles/PMC5999171/,Lynch syndrome,f current prediction models for ,: updating the PREMM5 model to i,TextQuoteSelector,TextPositionSelector,6171,6185,CRT_DS,yes,[CRT_DS][ALL],,acct:vanitha_hg@hypothes.is,Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers.,2019-10-11T12:04:18.940325+00:00
PjIfCu8xEemmfE-jX6yY4A,b53nbDmi,https://europepmc.org/articles/PMC5999171/," Colorectal Cancer recommends the use of either PREMM, MMRpredict or MMRpro to assess the probability of an individual carrying an MMR",e US Multi-Society Task Force on, mutation [34]. Since we did not,TextQuoteSelector,TextPositionSelector,32747,32881,NGD,no,NGD,,acct:vanitha_hg@hypothes.is,Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers.,2019-10-15T09:50:38.468241+00:00
ORqdMO8xEemBmkvSiAqvNQ,b53nbDmi,https://europepmc.org/articles/PMC5999171/," tumour tissue is available or where tumour tissue analysis failed, to assess whether an individual should be analysed for a germline MMR ",d also be used in cases where no,mutation.The US Multi-Society Ta,TextQuoteSelector,TextPositionSelector,32566,32704,NGD,no,NGD,,acct:vanitha_hg@hypothes.is,Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers.,2019-10-15T09:50:29.606342+00:00
M4ZPQO8xEemy998eSXh6gg,b53nbDmi,https://europepmc.org/articles/PMC5999171/, Colorectal Cancer recommends genetic evaluation if an individual’s risk of carrying an MMR,e US Multi-Society Task Force on, gene mutation is ≥ 5% according,TextQuoteSelector,TextPositionSelector,31632,31723,NGD,no,NGD,,acct:vanitha_hg@hypothes.is,Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers.,2019-10-15T09:50:20.615015+00:00
LOs73OwgEemAf7sq7pgTJQ,b53nbDmi,https://europepmc.org/articles/PMC5999171/,MUTYH,a pathogenic mutation in APC or ,", a variant of unknown clinical ",TextQuoteSelector,TextPositionSelector,14818,14823,CRT_GP,no,CRT_GP,,acct:vanitha_hg@hypothes.is,Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers.,2019-10-11T12:10:54.592426+00:00
LMzy2u8xEem6R3ceVfJL8A,b53nbDmi,https://europepmc.org/articles/PMC5999171/,"Lynch syndrome, they fail to identify PMS2 ",an individual is likely to have ,mutation carriers. The performan,TextQuoteSelector,TextPositionSelector,29213,29256,NGD,no,NGD,,acct:vanitha_hg@hypothes.is,Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers.,2019-10-15T09:50:09.270172+00:00
KGBl7OwgEemMY9eWHjZm8w,b53nbDmi,https://europepmc.org/articles/PMC5999171/,APC ,"d IHC, a pathogenic mutation in ","or MUTYH, a variant of unknown c",TextQuoteSelector,TextPositionSelector,14811,14815,MIS_GP,yes,[MIS_GP][ALL],,acct:vanitha_hg@hypothes.is,Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers.,2019-10-11T12:10:46.909590+00:00
Jva2Pu8xEem3DSPfZfPXDg,b53nbDmi,https://europepmc.org/articles/PMC5999171/,tumours in LS patients are characterized by microsatellite instability (MSI) and by loss of MMR ,"ter region [6–10]. As a result, ",protein expression in immunohist,TextQuoteSelector,TextPositionSelector,12171,12267,NGD,no,NGD,,acct:vanitha_hg@hypothes.is,Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers.,2019-10-15T09:49:59.355320+00:00
E6efOuwgEemD4rsOi3Q6uQ,b53nbDmi,https://europepmc.org/articles/PMC5999171/,CRC,"ict, which can only be used for "," patients. Until recently, all p",TextQuoteSelector,TextPositionSelector,13635,13638,"WT_GP,DS",yes,[WT_GP][DS][ALL],,acct:vanitha_hg@hypothes.is,Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers.,2019-10-11T12:10:12.130967+00:00
Dqa3NuwhEemKWCvmQCaYjA,b53nbDmi,https://europepmc.org/articles/PMC5999171/,cancer,r to prevent the development of ,. Our new model would also ident,TextQuoteSelector,TextPositionSelector,34703,34709,CRT_DS,no,CRT_DS,,acct:vanitha_hg@hypothes.is,Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers.,2019-10-11T12:17:13.209881+00:00
Dlq2rOwgEemt_Hu7CxBsWw,b53nbDmi,https://europepmc.org/articles/PMC5999171/,malignancies,r individuals with extracolonic ," and healthy individuals, as opp",TextQuoteSelector,TextPositionSelector,13544,13556,WT_DS,no,[WT_DS],,acct:vanitha_hg@hypothes.is,Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers.,2019-10-11T12:10:03.104074+00:00
AATdCOwgEemW-wM7pvcVGQ,b53nbDmi,https://europepmc.org/articles/PMC5999171/,tumour,ts eligible for LS screening in ," tissue. However, due to limited",TextQuoteSelector,TextPositionSelector,12755,12761,CRT_DS,yes,[CRT_DS][ALL],,acct:vanitha_hg@hypothes.is,Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers.,2019-10-11T12:09:39.219583+00:00
9bCK9OwgEemznZNwTlgv9w,b53nbDmi,https://europepmc.org/articles/PMC5999171/,Tumour,where [30].Family classification," characteristics, age at diagnos",TextQuoteSelector,TextPositionSelector,16147,16153,MIS_DS,no,MIS_DS,,acct:vanitha_hg@hypothes.is,Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers.,2019-10-11T12:16:31.346200+00:00
6YbU8OwfEemNMmfXFqwqUw,b53nbDmi,https://europepmc.org/articles/PMC5999171/,MSI, by microsatellite instability (,) and by loss of MMR protein exp,TextQuoteSelector,TextPositionSelector,12284,12287,WT_GP,yes,[WT_GP][ALL],,acct:vanitha_hg@hypothes.is,Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers.,2019-10-11T12:09:01.555520+00:00
6JWRDOwgEem6TC-bt9o3-w,b53nbDmi,https://europepmc.org/articles/PMC5999171/,EC,% (22)7% (6)0.12  ≥ 2 SDRs with ,0.3% (2)2% (2)0.07  Age EC (medi,TextQuoteSelector,TextPositionSelector,22401,22403,MIS_DS,yes,[MIS_DS][ALL],,acct:vanitha_hg@hypothes.is,Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers.,2019-10-11T12:16:09.348890+00:00
2i5IvOwfEemXcYN8LwiIag,b53nbDmi,https://europepmc.org/articles/PMC5999171/,microsatellite instability ,S patients are characterized by ,(MSI) and by loss of MMR protein,TextQuoteSelector,TextPositionSelector,12256,12283,WT_DS,no,[WT_DS],,acct:vanitha_hg@hypothes.is,Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers.,2019-10-11T12:08:35.680593+00:00
1VFG5uwfEempjJeHWS5mJg,b53nbDmi,https://europepmc.org/articles/PMC5999171/,tumours,"ter region [6–10]. As a result, ", in LS patients are characterize,TextQuoteSelector,TextPositionSelector,12212,12219,CRT_DS,yes,[CRT_DS][ALL],,acct:vanitha_hg@hypothes.is,Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers.,2019-10-11T12:08:27.642124+00:00
